BioLineRx (BLRX) Accounts Payables (2010 - 2026)

BioLineRx's Accounts Payables history runs 16 years deep, the most recent figure standing at $3.5 million for Q4 2025.

• In Q4 2025, Accounts Payables fell 37.44% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (down 37.44% YoY), while the FY2025 annual figure was $3.5 million, down 37.44% from the prior year.
• Accounts Payables for Q4 2025 stood at $3.5 million, down from $3.5 million in the prior quarter.
• The five-year high for Accounts Payables was $10.9 million in Q4 2023, with the low at $3.5 million in Q2 2025.
• The 5-year median for Accounts Payables is $5.8 million (2021), against an average of $6.1 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 56.03% in 2023, then sank 48.63% in 2024.
• BioLineRx's Accounts Payables stood at $5.6 million in 2021, then grew by 25.13% to $7.0 million in 2022, then soared by 56.03% to $10.9 million in 2023, then sank by 48.63% to $5.6 million in 2024, then plunged by 37.44% to $3.5 million in 2025.
• Business Quant data shows BLRX's Accounts Payables at $3.5 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.